EUVIMEDEUVIMED entdecken
Crossref

Enabling Personalized Dose Formulation by Evaporative Crystallization Process

Nicole M Torres-Colón, Lesly Carmona-Sarabia, Aliou Mbodji, Indumathi Sathisaran, Jean-Christophe M Monbaliu, Cornelis P Vlaar, Jorge Duconge, Rodolfo J Romañach, Torsten Stelzer

Pharmaceutical Research · 2026

DOI: 10.1007/s11095-026-04148-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Research, 2026. Verfasst von Nicole M Torres-Colón und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Puerto Rico, Mayagüez Campus, Mayagüez, Puerto Rico, 00681, USA. Hauptthemen laut MEDLINE: Warfarin. Die Arbeit nennt 93 Literaturangaben. Gefördert von: NASA, Puerto Rico Space Grant Consortium, National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Evaluating a solution-based drug impregnation strategy for individualized dose formulation of warfarin sodium isopropanol (WS-IPA), a drug with a narrow therapeutic index, using microcrystalline cellulose (MCC) placebo tablets as porous carrier. METHODS: Two formulation strategies were investigated: Add dissolved WS-IPA dropwise to a tablet, followed by solvent evaporation (M1) and dropwise addition coupled with antisolvent crystallization (M2). The tablets were characterized using powder X-ray diffraction and Raman spectroscopy for solid-form assessment. Scanning electron microscopy with energy-dispersive spectroscopy was used to visualize drug distribution and morphology. Principal component analysis was applied for Raman spectra to identify spectral differences and developed partial least squares (PLS) regression to determine WS-IPA content. RESULTS: M1 resulted in amorphous WS-IPA under the conditions studied. In contrast, the antisolvent crystallization strategy (M2) promoted the formation of crystalline WS-IPA within the MCC tablets. The M2 tablets met USP dissolution requirements similar to commercial tablets (Coumadin®). External Raman PLS model validation demonstrated the potential for non-destructive WS-IPA content estimation across individualized doses, with a Root Mean Square Error of Prediction of 0.35 mg. CONCLUSION: M2 with Raman-based process analytical technology enabled crystallization control and non-destructive tablet analysis for the flexible production of individualized solid dosage forms of WS-IPA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WarfarinCrystallizationTabletsSpectrum Analysis, RamanCelluloseChemistry, PharmaceuticalX-Ray DiffractionSolubilityDrug Compounding2-PropanolSolventsLeast-Squares AnalysisBulk Drugs

Stichwörter der Autor:innen

antisolvent crystallizationdrug impregnationpersonalized formulationsolid dosagesolid form control

Substanzen

TabletsCellulosemicrocrystalline celluloseWarfarin2-PropanolSolventsBulk Drugs

Autor:innen und Institutionen

  • Department of Chemistry, University of Puerto Rico, Mayagüez Campus, Mayagüez, Puerto Rico, 00681, USA.
  • Crystallization Design Institute, Molecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico, 00926, USA.
  • Department of Chemistry, University of Puerto Rico, Cayey Campus, Cayey, Puerto Rico, 00736, USA.
  • Department of Pharmaceutical Sciences, Medical Sciences Campus, University of Puerto Rico, San Juan, Puerto Rico, 00936, USA.
  • Center for Integrated Technology and Organic Synthesis, MolSys Research Unit, University of Liège, B-4000, Liège (Sart Tilman), Belgium.
  • WEL Research Institute, Avenue Pasteur, 6, 1300, Wavre, Belgium.

Förderung

  • NASA
  • Puerto Rico Space Grant Consortium
  • National Science Foundation
  • National Aeronautics and Space Administration

Zitieren

APA

Torres-Colón, N. M., Carmona-Sarabia, L., Mbodji, A., Sathisaran, I., Monbaliu, J. M., Vlaar, C. P., Duconge, J., Romañach, R. J., & Stelzer, T. (2026). Enabling Personalized Dose Formulation by Evaporative Crystallization Process. Pharmaceutical Research. https://doi.org/10.1007/s11095-026-04148-7

Vancouver

Torres-Colón NM, Carmona-Sarabia L, Mbodji A, Sathisaran I, Monbaliu JM, Vlaar CP, et al. Enabling Personalized Dose Formulation by Evaporative Crystallization Process. Pharmaceutical Research. 2026. doi:10.1007/s11095-026-04148-7

BibTeX
@article{TorresColn2026,
  author = {Torres-Colón, Nicole M and Carmona-Sarabia, Lesly and Mbodji, Aliou and Sathisaran, Indumathi and Monbaliu, Jean-Christophe M and Vlaar, Cornelis P and Duconge, Jorge and Romañach, Rodolfo J and Stelzer, Torsten},
  title = {Enabling Personalized Dose Formulation by Evaporative Crystallization Process},
  journal = {Pharmaceutical Research},
  year = {2026},
  doi = {10.1007/s11095-026-04148-7}
}
Kostenlos starten →